UPC CFI 434/2024

At the UPC: Edwards Lifesciences Group (57 cases)·Meril Group (60 cases)

• 2025-10-20
  Revocation ActionPublic

  Summary: Decision of the Paris Central Division (Paris Seat) dated 20 October 2025 in the revocation action by Meril entities against Edwards Lifesciences Corporation and the counterclaim for infringement by Edwards regarding EP 4 151 181 B1 (prosthetic heart valve technology). The revocation action was rejected; however, the patent was maintained only in the form of Auxiliary Request 2 (amended). The infringement counterclaim was granted: Meril entities were found to infringe claims 1, 4, 6–12 as amended. Edwards was granted an injunction preventing Meril from all infringing acts with products according to those claims in Contracting Member States, with an exception for XL-size valves (exceeding 30 mm) which was denied on proportionality grounds. Meril was ordered to provide information on infringing products, recall and destroy infringing products, and publish the decision in five media. Damages are to be determined in separate proceedings. Costs of the counterclaim were borne by Meril jointly and severally; costs of the revocation action were shared (each party bears own costs given the patent amendment dynamic).

  Show the legal issues (6)

  • Inventive step assessment using holistic approach
  • Revocation action versus patent amendment
  • Infringement counterclaim
  • Proportionality of injunction for XL-size medical devices
  • Public interest exception to injunctive relief under Art. 63(1) UPCA
  • Recall and publication orders